A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
A phase 2 trial of Abemaciclib and Temozolomide in glioma & glioblastoma, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy is a phase 2 interventional study registered as NCT06413706 by Eli Lilly and Company, with 45 participants enrolled, started 2024-10-25 and due to reach its primary completion in 2027-02. Interventions recorded: Abemaciclib and Temozolomide.
Similar pages
not linked directly; found by shared links- TrialCAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Shares Abemaciclib, Temozolomide, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialA Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialPh I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialJK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialSonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.